MoneyWorks4Me

Zydus Lifesciences informs about press release

25 Oct 2023 Evaluate

Zydus Lifesciences has informed that it enclosed a copy of press release dated October 25, 2023 titled ‘Zydus Lifesciences initiates Phase II clinical trial of ZYIL1, a novel oral NLRP3 inflammasome inhibitor in patients with Amyotrophic Lateral Sclerosis (ALS)’.

The above information is a part of company’s filings submitted to BSE.


Peers
Company Name CMP
Sun Pharma. Inds. 1745.00
Dr. Reddys Labs. 1242.00
Cipla 1331.00
Lupin 1953.75
Zydus Lifesciences 1113.00
View more..